Access said it will provide CobOral and CobaCyte siRNA formulations for evaluation of gene knockdown following oral and intravenous administration. RNAi is initiated by introducing small fragments of
A multi-center clinical study, whic involved 442 patients and used European Union (EU) approved cetuximab, led to the approval. In the trial, 222 patients received cetuximab plus cisplatin
The company which works for The National Institutes of Health (NIH), has been awarded funding from Capital Management for the NIH Integrated Research Facility (IRF) commissioning support project,
The contract is valued at up to $24m for the upcoming two years. The company expects to facilitate the development of Rx100, a radiomitigant countermeasure drug used against
The program intends to develop an advanced system for early cancer detection by employing acoustic liquid handling for arraying and MALDI mass spectrometry preparation. Stanford University Canary Center
As per the agreement, ORCA will receive €1,058,000 to carry out the first phase of the project, with an expected additional funding of about €5m on achieving specific
Under the terms of the deal, Perrigo will supply its Bright Beginnings infant formula brand to Brilite. Brilite, on the other hand, will exclusively source all its infant
The fast track status will facilitate to develop and expedite the review of drugs intended to treat serious or life-threatening conditions. The fast track priority review products are
The transaction is expected to close by the end of 2011, subject to routine closing conditions, including Hart-Scott-Rodino antitrust approval. Oceana Business Development executive vice president Gregory Stokes
Recombinant human interleukin-7 (CYT107) is a critical immune-modulator for immune T-cell recovery and enhancement. ECLIPSE II is an open-label, dose-escalating study, where CYT107 was administered subcutaneously, one injection
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.